Full Text:   <1830>

CLC number: R543.3

On-line Access: 

Received: 2001-11-29

Revision Accepted: 2002-01-15

Crosschecked: 0000-00-00

Cited: 0

Clicked: 3979

Citations:  Bibtex RefMan EndNote GB/T7714

-   Go to

Article info.
1. Reference List
Open peer comments

Journal of Zhejiang University SCIENCE A 2002 Vol.3 No.3 P.371-373

http://doi.org/10.1631/jzus.2002.0371


Application of GlycoProtein IIb/IIIa antagonist (Integrilin) in peri-percutaneous transluminal catheter angioplasty and stent implantation in Chinese


Author(s):  WANG Jia-nan, SUN Yong

Affiliation(s):  Department of Cardiology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou 310016, China

Corresponding email(s):   wang_jian_an@163.net

Key Words:  GPIIb/IIIa receptor antagonist, Integrilin, Percutaneous translumind catheter angioplasty (PTCA), Stent


Share this article to: More

WANG Jia-nan, SUN Yong. Application of GlycoProtein IIb/IIIa antagonist (Integrilin) in peri-percutaneous transluminal catheter angioplasty and stent implantation in Chinese[J]. Journal of Zhejiang University Science A, 2002, 3(3): 371-373.

@article{title="Application of GlycoProtein IIb/IIIa antagonist (Integrilin) in peri-percutaneous transluminal catheter angioplasty and stent implantation in Chinese",
author="WANG Jia-nan, SUN Yong",
journal="Journal of Zhejiang University Science A",
volume="3",
number="3",
pages="371-373",
year="2002",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.2002.0371"
}

%0 Journal Article
%T Application of GlycoProtein IIb/IIIa antagonist (Integrilin) in peri-percutaneous transluminal catheter angioplasty and stent implantation in Chinese
%A WANG Jia-nan
%A SUN Yong
%J Journal of Zhejiang University SCIENCE A
%V 3
%N 3
%P 371-373
%@ 1869-1951
%D 2002
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.2002.0371

TY - JOUR
T1 - Application of GlycoProtein IIb/IIIa antagonist (Integrilin) in peri-percutaneous transluminal catheter angioplasty and stent implantation in Chinese
A1 - WANG Jia-nan
A1 - SUN Yong
J0 - Journal of Zhejiang University Science A
VL - 3
IS - 3
SP - 371
EP - 373
%@ 1869-1951
Y1 - 2002
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.2002.0371


Abstract: 
Objective: to report the application of GPIIb/IIIa antagonist (integrilin) in peri-percutaneous transluminal catheter angioplasty and stent implantation in Chinese. Method: Twenty-one patients who underwent percutaneous transluminal catheter angioplasty(PTCA) and stent implantation were included. After arterial puncture, integrilin was injected at dose of 180 μg/kg, and then maintained at 2 μg/kg·min for 18 hours. Asprine, plavix(clopidogrel) and heparin were used at the same time. ACT, PT, KPTT and blood routine were routinely monitored. Results: All sheaths were drawn out 2 to 4 hours after the procedure.. There was no severe complication such as hematoma, acute and subacute thrombosis in coronary artery, or thrombocytopenia. ACT returned to less than 150 seconds in 2 hours in 15 patients; in 4 hours in 6 patients. There was no significant difference between the pre- and post-procedure value of PT and platelet count. KPTT was significantly higher than pre-procedure value at 2 hours after the procedure. No recurrence of angina pectoris was observed in the first nine patients within one year follow-up, and no restenosis occurred in stents in the five patients who had coronary angiography one year later. Conclusion: Application of GPIIb/IIIa receptor antagonist (integrilin) in peri-percutaneous transluminal catheter angioplasty and stent implantation in combination with aspirin and plavix could significantly reduce the dosage and duration of heparin with benefit of shortening the indwelling time of sheaths, but did not increase risk of bleeding or lead to thrombosis in stent.

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference

[1] Frishman, W.H., Burns, B., Atac, B, et al.,1995. Novel antiplatelet therapies for treatment of patients with ischemic heart disease. Am Heart J, 130(4): 877-92.

[2] Kereiakes, D.J., 1998. Preferential benefits of platelet glycoprotein IIb/IIIa receptor blockade: specific considerations by device and disease state. Am J cardiol, 81(7A): 49E-54E.

[3] Pitts, W.R., Lange, R A., 1999. Platelet glycoprotein IIb/IIIa receptor blockade: lessening the risk of coronary interventions. Thromb Haemost, 82 (suppl 1):136-138.

Open peer comments: Debate/Discuss/Question/Opinion

<1>

Please provide your name, email address and a comment





Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - 2022 Journal of Zhejiang University-SCIENCE